Biopol Chemicals Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Biopol Chemicals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹108
Per ShareLot Size
1200 Shares
Minimum Investment
₹1,29,600
Issue Size
₹31.26 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.08%
QIB Quota
25.02%
NII Quota
39.9%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Biopol Chemicals Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
89.88%
Promoter Holding (Post-Issue)
65.81%
Issue Type
Book Building - SME
ISIN
INE0XW001014
About the Company
Our Company is engaged in the business of trading, manufacturing and distribution of specialty chemicals under the categories of silicones, emulsifiers, biochemicals and polyelectrolytes. Our product portfolio consists of 66 products which comprises of 40 silicone-based products, 5 emulsifier-based products, 15 biochemical products and 6 polyelectrolyte products. These products are used in applications across various industry segments, including softeners, emulsions and hardeners for textiles; silicone fluids and cleaning chemicals for home care; silicone adjuvants and surfactants in agriculture; and release agents in industrial chemicals.
Industry Overview
Covering more than 80,000 commercial products, India's chemical industry is extremely diversified and can be broadly classified into bulk chemicals, specialty chemicals, agrochemicals, petrochemicals, polymers, and fertilisers. India is the 6th largest producer of chemicals in the world and 3rd in Asia, contributing 7% to India's GDP. India's chemical sector, which was estimated to be worth around Rs. 21,50,750 crore (US$ 250 billion) in 2024, is anticipated to grow to US$ 300 billion by 2025 and Rs. 86,03,000 (US$ 1 trillion) by 2040. This industry remains an active hub of opportunities, even in an environment of global uncertainty.
Company History
Our Company was originally incorporated on April 12, 2023 under the name "Biopol Chemicals Private Limited" under the provisions of the Companies Act, 2013 with the Registrar of Companies, Central Registration Centre. Subsequently, our Company acquired the sole proprietorship firm of Mr. Santanu Sarkar i.e. "United Chemical Company", pursuant to a Business Takeover Agreement dated September 25, 2023, effective from September 30, 2023. Thereafter, the status of the Company was changed to public limited Company and the name of our Company was changed to "Biopol Chemicals Limited" vide Special Resolution passed by the Shareholders at the Extra-Ordinary General Meeting of our Company held on February 22, 2024. The fresh certificate of incorporation consequent to conversion was issued on May 16, 2024 by Registrar of Companies, Central Registration Centre. The Corporate Identification Number of our Company is U20297GJ2023PLC140117.
Products & Services
- The Company is engaged in the business of trading, manufacturing and distribution of specialty chemicals under the categories of silicones, emulsifiers, biochemicals and polyelectrolytes.
Growth Strategy
- Purchase of an industrial land and expansion of geographical presence in the state of Gujarat.
- Reduce debt levels and improve Debt to Equity Ratio.
- Maintaining cordial relationships with our suppliers and employees
- Expansion of customer base.
- Participation in upcoming exhibitions for product awareness.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of up to 28,94,400 equity shares of face value of Rs.10/- each (the "Equity Shares") of Biopol Chemicals Limited ("the Company" or "Biopol" or "the Issuer") for cash at a price of Rs. 108 per equity share including a share premium of Rs. 98 per equity share (the "Issue Price") aggregating to Rs. 31.26 crores ("the Issue"), of which up to 1,51,200 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 108 per equity share including a share premium of Rs. 98 per equity share aggregating to Rs. 1.63 crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e., net issue of up to 27,43,200 equity shares of face value of Rs. 10/- each at a price of Rs. 108 per equity share including a share premium of Rs. 98 per equity share aggregating to Rs. 29.63 crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.79% and 25.39% respectively of the post issue paid up equity share capital of the company. The company, in consultation with the brlm, may consider issuing 3,50,400 equity shares as a pre-ipo placement by the company for an aggregate amount up to Rs. [*]. The pre-ipo placement, if undertaken, will be at a price to be decided by the company in consultation with the brlm. If the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) Rules, 1957, as amended. the pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue and the proceeds of the pre-ipo placement shall be utilized towards general corporate purposes proceeds. prior to the completion of the issue, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the issue or the issue may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). Price Band: Rs. 108 per equity share of face value Rs.10/- each. The floor price is 10.8 times of the face value of the equity shares. Bids can be made for a minimum of 2,400 equity shares and in multiples of 1,200 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Our Order Book.
- Our Manufacturing Unit.
- Quality Certification and Quality Assurance.
- Strategic presence in Gujarat and West Bengal.
- Experienced Promoter and Management Team.
- The company's speciality chemicals are used in the textile segment and its business is significantly dependent on the textile industry. Any adverse developments in that industry may materially and adversely affect the company's business, financial condition, results of operations and cash flows.
- A significant portion of its revenue is derived from customers located in West Bengal, Gujarat and Bangladesh. Any adverse developments in these regions may materially and adversely affect the company's business, financial condition, results of operations and cash flows.
- The Company is dependent on a limited number of suppliers for the procurement of critical raw materials. The loss of any of these suppliers or disruption in supply may materially and adversely affect its business operations, financial condition, results of operations and cash flows.
- The company's revenue is derived through a combination of direct sales and distributor-driven sales, and any disruption or inefficiency in either channel may materially and adversely affect its business, financial condition, results of operations and cash flows. Additionally, we do not have long-term agreements with certain distributors, which exposes it to the risk of losing them or facing unfavourable commercial terms.
- The company depends on a limited number of key customers for a substantial portion of its revenue and any loss of, or reduction in business from such customers could materially and adversely affect the company's business, results of operations, cash flows and financial condition. The company does not have any agreements with these customers for repeat business, and the comoany cannot assure that the company will generate the same quantum of business, or any business at all, from them. Any decline in the quality of its products or services, growing competition, changes in customer preferences, or a shift by customers to other suppliers could adversely affect our ability to retain these key customers. Loss of business from one or more of our major customers could materially reduce the company's revenue and profitability.